Early data from Phase III Northstar-2 study of LentiGlobin

24 June 2017
2019_biotech_test_vial_discovery_big

US clinical-stage biotech firm bluebird bio’s (Nasdaq: BLUE) shares closed down 5.5% at $112.00, having fallen as low as $105.90 earlier on Friday, after the firm released what was apparently positive data on its lead candidate to be presented at the European Hematology Association (EHA) Annual Meeting in Madrid, Spain on June 25.

The company announced early interim data from the ongoing Northstar-2 (HGB-207) Phase III clinical study of LentiGlobin drug product in patients with transfusion-dependent beta-thalassemia (TDT) and non-β0/β0 genotypes.

“Northstar-2 is our first study to utilize our improved LentiGlobin drug product manufacturing process to increase the drug product vector copy number and percent of cells transduced. The first patient treated in this study exemplifies the promise of gene therapy, discontinuing blood transfusions approximately a month after treatment and achieving a normal level of total hemoglobin production at six months post-treatment,” said David Davidson, chief medical officer of bluebird bio. “These early results suggest that the improved manufacturing process results in consistently higher drug product vector copy numbers (VCN) and lentiviral vector positive (LVV+) cells, which is correlated with higher production of HbAT87Q and ultimately may address known patient-to-patient variability,” Dr Davidson pointed out.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology